We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+0.23%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.56B
AUM Growth
-$299M
Cap. Flow
+$625M
Cap. Flow %
8.26%
Top 10 Hldgs %
53.85%
Holding
87
New
11
Increased
24
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
RXRX icon
Recursion Pharmaceuticals
RXRX
+$134M
2
CLYM
Climb Bio
CLYM
+$122M
3
ACLX
Arcellx
ACLX
+$87.2M
4
EVH icon
Evolent Health
EVH
+$71M
5
RNAM
Avidity Biosciences
RNAM
+$60.8M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$91.9M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$54.6M
3
CTKB icon
Cytek Biosciences
CTKB
+$45.7M
4
VXRT
Vaxart
VXRT
+$20M
5
EYPT icon
EyePoint Inc
EYPT
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCCC icon
51
C4 Therapeutics
CCCC
$385M
$22.5M 0.3%
4,878,000
– –
ANRO icon
52
Alto Neuroscience
ANRO
$1.05B
$22.3M 0.29%
2,085,554
+700,063
+51% +$9.11M
IMTX icon
53
Immatics
IMTX
$1.18B
$20.3M 0.27%
1,750,000
– –
SERA icon
54
Sera Prognostics
SERA
$79.9M
$18M 0.24%
3,032,808
+1,008,587
+50% +$9.02M
JBIO
55
Jade Biosciences
JBIO
$1.2B
$15.3M 0.2%
262,631
+26,517
+11% +$17.6M
HOWL icon
56
Werewolf Therapeutics
HOWL
$17.2M
$15M 0.2%
6,144,881
– –
CRVO icon
57
CervoMed
CRVO
$23.9M
$14M 0.19%
817,120
-44,453
-5% -$972K
PLRX icon
58
Pliant Therapeutics
PLRX
$64.4M
$13.8M 0.18%
1,281,000
– –
NRIX icon
59
Nurix Therapeutics
NRIX
$2.41B
$13.6M 0.18%
+650,000
New +$10.1M
INSM icon
60
Insmed
INSM
$21.4B
$13.4M 0.18%
+200,000
New +$7.76M
ANTX icon
61
AN2 Therapeutics
ANTX
$193M
$11.9M 0.16%
5,551,295
– –
HELP
62
Cybin Inc
HELP
$485M
$11.9M 0.16%
1,158,012
-371,976
-24% -$4.87M
ZURA icon
63
Zura Bio
ZURA
$516M
$11.3M 0.15%
+3,217,503
New +$13.1M
ARVN icon
64
Arvinas
ARVN
$518M
$11.2M 0.15%
421,348
– –
RGLS
65
DELISTED
Regulus Therapeutics
RGLS
$11.2M 0.15%
6,250,000
– –
LXEO icon
66
Lexeo Therapeutics
LXEO
$324M
$10.8M 0.14%
672,712
+11,774
+2% +$171K
ACET icon
67
Adicet Bio
ACET
$85.2M
$9.12M 0.12%
471,313
– –
NUVL
68
DELISTED
Nuvalent
NUVL
$9.09M 0.12%
+119,789
New +$8.52M
MGNX icon
69
MacroGenics
MGNX
$235M
$8.85M 0.12%
2,082,021
– –
BOLD
70
Boundless Bio
BOLD
$56.2M
$8.44M 0.11%
2,180,631
– –
CMRX
71
DELISTED
Chimerix, Inc.
CMRX
$7.71M 0.1%
8,800,000
– –
PCSC
72
DELISTED
Perceptive Capital Solutions
PCSC
$7.54M 0.1%
+750,000
New +$7.55M
MGX icon
73
Metagenomi Therapeutics
MGX
$44.8M
$6.03M 0.08%
1,477,749
-266,666
-15% -$1.83M
TARA icon
74
Protara Therapeutics
TARA
$220M
$3.95M 0.05%
+1,900,000
New +$5.56M
SRZN icon
75
Surrozen
SRZN
$258M
$3.09M 0.04%
+282,580
New +$2.92M
1 2
3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, RA Capital Management held 87 positions worth $7.56B, down 3.8% from $7.86B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

RA Capital Management deployed $625M of net new capital in Q2 2024, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Recursion Pharmaceuticals: 15,384,615 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was iTeos Therapeutics, an estimated $12.9M trimmed.

  • RA Capital Management's largest Q2 2024 buy was Recursion Pharmaceuticals: 15,384,615 shares worth $115M.
  • RA Capital Management added most to Climb Bio in Q2 2024, an estimated $122M increase.
  • RA Capital Management's biggest Q2 2024 reduction was iTeos Therapeutics, cutting an estimated $12.9M.
  • RA Capital Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $91.9M.
  • RA Capital Management's ten largest holdings make up 54% of its $7.56B portfolio in Q2 2024.
  • RA Capital Management opened 11 new positions and closed 9 in Q2 2024.
  • RA Capital Management's portfolio value fell 3.8% quarter-over-quarter to $7.56B.

Based on RA Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.